Filament Begins First Ever FDA-Approved Clinical Trial On Naturally-Derived Psychedelic Drugs

Filament Health Announces Third Quarter 2024 Financial Results And Operational Highlights

These patients are considering MAiD. They say Canada has made it harder to access magic mushrooms — a treatment giving them reason to live

Innovative trial will use psilocybin to target relapse in opioid addiction